In October, 2021 the Lancet published the much awaited results of the fluvoxamine arm of its ongoing investigation into repurposed drugs to treat COVID-19. The results were positive showing a reduction in hospitalization and mortality in favour of the intervention arm. Since then, there has been little movement at the station when it comes to publicity for the well-established and generic anti-depressant.